July 22 (Reuters) - Life sciences firm Danaher ( DHR )

raised its annual profit forecast on Tuesday, banking on

resilient demand for its diagnostic testing tools and services.

However, the Washington, D.C.-based company's shares

declined 3% to $182 in premarket hours, after it maintained its

target for full-year core revenue growth.

Excluding one-time items and foreign currency impacts,

Danaher ( DHR ) expects its annual core revenue to grow about 3% from a

year ago. It also reiterated that proposed tariffs could add

"several hundred million dollars" to its costs this year.

The company's sales came in at $5.94 billion during the

second quarter, helped in part by a weaker dollar, largely in

line with analysts' average expectation of $5.84 billion,

according to data from LSEG.

Danaher's ( DHR ) clinical lab diagnostics business grew across most

regions, which helped offset declining revenues in China.

Revenues took a hit in China, which makes up about 12% of

the company's sales, due to the country's volume-based

procurement policies where the government buys products in bulk

at a cheaper price.

Analysts have warned that Danaher ( DHR ) will continue to grapple

with sliding revenues in China and weakness in the company's

life sciences unit, through which it sells instruments used to

understand the causes of diseases and manufacture new therapies.

Like its peers, Danaher ( DHR ) is seeing soft demand and high costs

related to these products.

Danaher ( DHR ) expects its third-quarter revenue to grow at a

low-single-digit percentage rate from a year earlier.

The company forecast annual adjusted profit in the range of

$7.70 to $7.80 per share, compared with its previous projection

of $7.60 to $7.75.

Analysts were expecting annual profit of $7.70 per share,

according to data compiled by LSEG.

Separately, Danaher ( DHR ) announced that Matthew Gugino will be

succeeding long-time CFO Matthew McGrew, effective February 28,

2026.